Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells

I. Tsang Chiang, Yu Chang Liu, Wei Hsun Wang, Fei Ting Hsu, Hong Wen Chen, Wuu Jyh Lin, Wen Yi Chang, Jeng Jong Hwang

研究成果: 雜誌貢獻文章同行評審

59 引文 斯高帕斯(Scopus)

摘要

Invasion by hepatocellular carcinoma (HCC) has been reported to occur via the up-regulation of nuclear factorkappaB (NF-κB). Sorafenib can improve the overall survival in patients with HCC, however, the association of its inhibitory mechanisms with the inactivation of NF-κB remains unclear. Here, Huh7 cell line transfected with NF-κB-luc2 vector was used to study the effects of sorafenib on NF-κB activity, on expressions of matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF), which were induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA increased the NF-κB activity and the expressions of MMP-9 and VEGF significantly, but its effects were suppressed by sorafenib in a dose-dependent manner. Similar results were found with PD98059, an inhibitor of extracellular signalregulated kinase (ERK). Furthermore, transfection of Huh7 cell with an inhibitor of kappaB-α mutant vector, led to reduced TPA-induced MMP-9 and VEGF mRNA expressions. Sorafenib inhibits TPA-induced MMP-9 and VEGF expressions via the suppression of ERK/NF-κB pathway in HCC cells.
原文英語
頁(從 - 到)671-682
頁數12
期刊In Vivo
26
發行號4
出版狀態已發佈 - 7月 2012
對外發佈

ASJC Scopus subject areas

  • 醫藥 (全部)
  • 生物化學、遺傳與分子生物學 (全部)
  • 藥理

指紋

深入研究「Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells」主題。共同形成了獨特的指紋。

引用此